Effectiveness and Acceptability of LISEFEX® (Liposomal Iron With Vitamin C and Fiber) in People With Iron Deficiency Anemia.

Effectiveness and Acceptability of a Liposomal Iron Supplement With Vitamin C and Fiber (LISEFEX®): Observational, Descriptive, Prospective, Longitudinal, Multicenter Study in Mexican Subjects Diagnosed With Mild to Moderate Iron Deficiency Anemia.

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT07483645

Enrollment

Registered

2026-03-19

Start date

2025-05-06

Completion date

2026-03-30

Last updated

2026-03-19

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Iron Deficiency Anemia

Keywords

Anemia, iron supplementation liposomal, hemoblogin, iron deficiency anemia

Brief summary

Observational, descriptive, prospective, longitudinal, multicenter, non-interventionist and multicentric study in Mexican subjects diagnosed with mild to moderate iron deficiency anemia (ADH). Main objective:To evaluate the effectiveness and acceptability of LISEFEX® supplement in patients with mild to moderate iron deficiency anemia.Design The minimal risk study, no therapeutic interventions were carried out by the research team. The indication for supplementation with LISEFEX® was made by the treating physician as part of standard clinical practice, while the study was limited to systematic collection of clinical and laboratory information during participant follow-up.

Detailed description

The primary objective of this study was to describe the evolution of hemoglobin levels from baseline to weeks 1, 2, 4, 8 and 12 of supplementation with LISEFEX®. Secondary objectives, the aim is to describe various hematological, biochemical and safety parameters throughout the follow-up period in both cohorts. In particular, the percentage of reticulocytes was evaluated basal and in weeks 2, 4, 8 and 12 of supplementation. Also, the values of mean corpuscular volume (MCV), mean corpuscular hemoglobin (HCM) and corpuscular hemoglobin concentration were described mean (CHCM) baseline and follow-up weeks 1, 2, 4, 8, and 12.

Interventions

None listed

Study design

Observational model

COHORT

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

* Clinical diagnosis of iron deficiency anemia. * Candidates over 18 years. * Candidates with Informed Consent signed. * Candidates who have been instructed by their treating physician to start treatment with LISEFEX * Candidates with the ability to swallow substances orally.

Exclusion criteria

* Pregnancy or breastfeeding. * Having received any treatment in the last 3 months for iron deficiency anemia.

Design outcomes

Primary

Measure	Time frame
Hemoglobin level	12 weeks

Countries

Mexico

Contacts

PRINCIPAL_INVESTIGATORIris E Torres Garcia, Medico

PRINCIPAL_INVESTIGATORLeonardo R Aguilar, Medico

PRINCIPAL_INVESTIGATORWilly Nava, Medico

PRINCIPAL_INVESTIGATOREdgar U Coronado, Medico

Outcome results